NewsRoom Articles - Page 663 of 750

ThursdayFeb 16, 2017 9:30 am

Aeterna Zentaris (NASDAQ: AEZS) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

Aeterna Zentaris (NASDAQ: AEZS) is a specialty biopharmaceutical company engaged in developing and commercializing Zoptrex™, a novel cytotoxic compound. To ensure development, registration and launch of the product, the company intends to license out certain commercial rights to Zoptrex™. The company also actively seeks opportunities to in-license and acquire products for U.S. commercialization. For more information, visit the company's website at www.aezsinc.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW…

ThursdayFeb 16, 2017 9:30 am

Ener-Core (ENCR) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

Ener-Core (OTC: ENCR) designs, develops and manufactures products that are based on power oxidizer technologies. The company's proprietary technology provides an alternative to traditional methods of destroying gaseous pollution by enabling industrial facilities to generate on-site power from their waste gases. Its products include Ener-Core PowerStation EC250 and Ener-Core Powerstation KG2-3G/GO, which have applications in landfills, distilleries, and wastewater treatment plants, as well as various industrial processes. For more information, visit the company's website at www.ener-core.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted…

ThursdayFeb 16, 2017 9:00 am

ChineseInvestors.com, Inc. (CIIX) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

ChineseInvestors.com (OTCQB: CIIX), headquartered in Los Angeles, with offices in New York City and Shanghai China, engages in providing a wide range of products, services and information for the global Chinese population. Founded in 1999, CIIX endeavors to be an innovative company providing (a) real-time market commentary, analysis, and educational related services in Chinese language character sets (traditional and simplified); (b) support services to various partners; (c) consultative services to smaller private companies considering becoming a public company; (d) advertising and public relation related support services; and (e) other services we may identify having the potential to create value or…

ThursdayFeb 16, 2017 9:00 am

Actinium Pharmaceuticals (NYSE: ATNM) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

Actinium Pharmaceuticals (NYSE: ATNM) is a biopharmaceutical company developing innovative targeted payload immunotherapies for the treatment of advanced cancers. The company's radioimmunotherapy product candidates are based on the combination of the cancer targeting precision of monoclonal antibodies (mAb) that seek out specific types of cells combined with the cytotoxic killing power of radioisotopes that unleash their energy once they have reached their target. For more information, visit the company's website at www.actiniumpharma.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution…

ThursdayFeb 16, 2017 8:30 am

Bridgeline Digital, Inc. (NASDAQ: BLIN) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

Bridgeline Digital (NASDAQ: BLIN), The Digital Engagement Company™, helps customers to maximize the performance of their mission critical websites, intranets and online stores. The company’s iAPPS platform deeply integrates web content management, eCommerce, eMarketing, social media management, and web analytics to help marketers deliver digital experiences that attract, engage and convert their customers across all channels. Headquartered in Burlington, Massachusetts, Bridgeline has thousands of quality customers that range from small- and medium-sized organizations to Fortune 1000 companies. For more information, visit the company’s website at www.bridgelinedigital.com About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and…

ThursdayFeb 16, 2017 8:30 am

Cellectar Biosciences (NASDAQ: CLRB) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

Cellectar Biosciences (NASDAQ: CLRB) is engaged in the development of targeted phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. It offers CLR 131, a PDC radiotherapeutic product candidate currently being evaluated in a phase I study for the treatment of relapse or refractory multiple myeloma; CLR 125, a cancer-targeting radiotherapeutic is under pre-clinical investigation for the treatment of micrometastatic disease ; CLR 124, a cancer-targeting positron emission tomography (PET) imaging PDC for the selective detection of tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting NIR-fluorophore optical imaging PDC for intraoperative tumor…

WednesdayFeb 15, 2017 4:00 pm

Oramed Pharmaceuticals (NASDAQ: ORMP) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

Oramed Pharmaceuticals (NASDAQ: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (PODTM) technology is based on over 30 years of research by scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). The company completed multiple phase II clinical trials of ORMD-0801 under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 analog capsule (ORMD-0901).…

WednesdayFeb 15, 2017 3:30 pm

Pluristem Therapeutics (NASDAQ: PSTI) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

Pluristem Therapeutics (NASDAQ: PSTI) operates as a bio-therapeutics company in Israel. The company focuses on the research, development, clinical trials, and manufacture of cell therapeutics products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions. It develops placenta expanded (PLX) products, including PLX-PAD cells that are in Phase-II clinical trial for use in the treatment of peripheral and cardiovascular diseases, as well as for the treatment of orthopedic diseases. For more information, visit the company’s website at www.pluristem.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of…

WednesdayFeb 15, 2017 3:00 pm

Oncosec Medical, Inc. (NASDAQ: ONCS) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

Oncosec Medical (NASDAQ: ONCS) is a biotechnology company that designs, develops, and commercializes gene therapies, therapeutics, and proprietary medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer in the United States. Its lead product candidate is the ImmunoPulse IL-12, which is in Phase II clinical trial for various indications, including metastatic melanoma and triple negative breast cancer. ImmunoPulse is an electroporation delivery device used in combination with the company’s therapeutic product candidates, including DNA plasmids that encode for immunologically active agents, and to deliver the therapeutic directly into the tumor and promote an inflammatory…

WednesdayFeb 15, 2017 2:53 pm

CytoDyn Inc. (CYDY) PRO 140 Poster Presentation at HIV Conference

Attendees at the Conference on Retroviruses and Opportunistic Infections (February 13-16) at the Washington State Convention Center in Seattle received a two-year update on CytoDyn’s PRO 140 as a single-agent maintenance therapy for HIV-1 infection. The poster presentation is from Dr. Kush Dhody, Senior Director, Clinical Operations at Amarex Clinical Research, on behalf of CytoDyn Inc. (OTCQB: CYDY). A follow-up discussion reviewing five abstracts, hosted by Karl Salzwedel of the National Institutes of Health and under the theme ‘I Want a New Drug’, is also scheduled and expected to feature a panel of distinguished participants, including CytoDyn CEO Nader Pourhassan.…

Financial news and publishing for public and private companies

Contact us: 212.418.1217